
CanSinoBIO’s inhaled Covid vaccine candidate triggers immune response
An inhaled version of CanSino Biologics’ (CanSinoBIO) COVID-19 vaccine triggered immune responses without serious side effects, an early-stage clinical trial showed.
The two-dose candidate requires lower dosages than the injected ...